KURA
HOLD / NEUTRALMeanRevComposite
51.20
Technical
87.90
Fundamental
39.00
Rank
—
Price
13.59
Hurst
0.26
As of
Aug 26, 2026
Daily
Kura Oncology, Inc.
HealthcareBiotechnologyKura Oncology is a biopharmaceutical company developing cancer treatments based in San Diego. The company markets KOMZIFTI, an oral menin inhibitor, and is advancing darlifarnib through early-stage trials in combination with other therapies for solid tumors. Its pipeline also includes KO-7246 and additional menin inhibitors for both cancer and metabolic disorders.
Market cap
$912.7M
P/E (trailing)
—
P/E (forward)
-4.38
PEG ratio
—
Dividend yield
0.00%
Beta
0.47
52w range
7.36 – 13.90
Return on equity
-167.71%
Profit margin
0.00%
Revenue growth
+36.50%
Earnings growth
—
Price history
1Y: 10.26 (-0.1%) · range 7.40–13.59
Cycle position
42/ 100 cycle scoreAPPROACHING ENTRY
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 40 · WEAK SETUP · exit proximity 0
Conviction
30/ 100 · maturity 0%
Buildup.3310
EMA entry setup.4240
Fundamentals.2539
Volume profile
POC
10.87
Price vs POC
-5.6%
Overhead supply
62%
Runway
+2.7%
Value area 8.83–11.48 · 62% of 120d volume overhead · heavy supply
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -16.85% | +1.45% | mature |
| 40d | -24.50% | +1.45% | mature |